Madison, WI – According to filings with the U.S. Securities and Exchange Commission, Flugen is raising $8,500,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Paul Radspinner played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Flugen
At FluGen we’re dedicated to improving public health by developing a vaccine that can prevent disease caused by all forms of the deadly influenza virus. We are fighting a virus that mutates quickly and results in over 200,000 hospitalizations and up to 79,000 deaths in the U.S. alone. Worldwide, influenza causes 290,000 to 650,000 deaths every year. Based in Madison, Wisconsin, FluGen is developing M2SR, an influenza vaccine that is currently in human trials. We are committed to forging a new and more effective weapon in the fight against influenza.

To learn more about Flugen, visit http://flugen.com/

Contact:
Paul Radspinner, President and Chief Executive Officer
608-441-2729
pradspinner@flugen.com
https://www.linkedin.com/in/paul-radspinner-a851b610/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved